Business
Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Mexican Institute of Industrial Property (IMPI) has issued a Notice of Allowance for a new patent related to its breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, will provide composition of matter protection for the Company's novel approach to breast cancer treatment and prevention in Mexic
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"Notice of Allowance marks first Mexican patent to be issued on Anixa Breast Cancer Vaccine","length":90,"tagName":"p","attribs":{}},{"type":"text","content":"Expands global intellectual property coverage in markets with greater late-stage breast cancer diagnoses and higher triple-negative breast cancer incidence rates","length":161,"tagName":"p","attribs":{}},{"type":"text","content":"SAN JOSE, Calif., Jan. 27, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Mexican Institute of Industrial Property (IMPI) has issued a Notice of Allowance for a new patent related to its breast cancer vaccine technology. This patent, exclusively licensed from Cleveland Clinic, will provide composition of matter protection for the Company's novel approach to breast cancer treatment and prevention in Mexico.","length":574,"tagName":"p"},{"type":"image","alt":"Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)","displaySize":"","headline":null,"caption":"Anixa Biosciences, Inc. (PRNewsfoto/Anixa Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":119,"url":"https://media.zenfs.com/en/prnewswire.com/3ba55e340de170a9f97c46887c8c8549"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/4B69KZz1nJO8NbFw7Kh3Pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3ba55e340de170a9f97c46887c8c8549","width":400,"height":119}},"href":"https://mma.prnewswire.com/media/602982/ITUS_Corporation_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"With this allowance, Anixa continues to expand the international scope of its intellectual property portfolio, reinforcing its leadership in the field of cancer immunotherapy. The Mexican patent complements patents issued in the United States and other key global jurisdictions, and represents an important step toward future regulatory and commercial efforts outside the U.S.","length":376,"tagName":"p"},{"type":"text","content":""This newly allowed patent continues the broad international recognition of the novelty and potential of our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As ...